DNX-04042

DNX-04042 is an investigational, orally available small-molecule kinase inhibitor co-developed by Dynamix Pharmaceuticals and CleveXel Pharma for the treatment of inflammatory and autoimmune diseases, particularly arthritis. It is designed as a potent dual inhibitor of spleen tyrosine kinase (SYK) and Janus kinase 3 (JAK3), with significant selectivity within the JAK family, thereby modulating B‑cell receptor signaling and common γ-chain cytokine signaling pathways that drive immune activation and inflammation in diseases such as rheumatoid arthritis.[1][5][11] DNX-04042 is also referenced in patent literature as a parent JAK inhibitor that can be modified into lipid prodrugs to improve oral bioavailability and pharmacokinetic properties, underscoring its role as a small-molecule JAK-targeting agent.[9]